Orchard Therapeutics, a UK-based gene therapy spinout of University College London, closed a $150m oversubscribed series C round featuring medical marketing group Medison and healthcare management services provider Sphera Global Health Care on Monday.
The round was led by Deerfield Management. Medison participated through its strategic investment vehicle, Medison Ventures.
Temasek, the Singaporean state-owned investment firm, also participated, as did RA Capital Management, Venrock, Foresite Capital, Perceptive Advisors, Cormorant Asset Management, ArrowMark Partners, Driehaus Capital Management, Ghost Tree Capital, Baillie Gifford, RTW Investments, Cowen Healthcare Investments and Agent Capital.
Orchard is working on gene therapies for rare, potentially fatal diseases and the series C proceeds will support work on its most developed drug candidates.
The company’s lead product candidates include treatments for metabolic disorder Adenosine deaminase deficiency, immune disorder Wiskott-Aldrich syndrome and a lysosomal storage disease called metachromatic leukodystrophy.
Orchard had raised a total of more than $140m when pharmaceutical…
